(Q36641415)

15 August 2017

Autoantibodies and autoimmune disease during treatment of children with chronic hepatitis C. (English)

1 reference

15 August 2017

1 reference

1 reference

12

Bruce A Barton

1 reference

15 August 2017

1

Jean P Molleston

1 reference

15 August 2017

William Mellman

2

1 reference

15 August 2017

Michael R Narkewicz

3

1 reference

15 August 2017

William F Balistreri

4

1 reference

15 August 2017

Regino P Gonzalez-Peralta

5

1 reference

15 August 2017

Maureen M Jonas

6

1 reference

15 August 2017

Steven J Lobritto

7

1 reference

15 August 2017

Parvathi Mohan

8

1 reference

15 August 2017

Karen F Murray

9

1 reference

15 August 2017

Dolores Njoku

10

1 reference

15 August 2017

Philip Rosenthal

11

1 reference

15 August 2017

Monica V Talor

13

1 reference

15 August 2017

Irene Cheng

14

1 reference

15 August 2017

Kathleen B Schwarz

15

1 reference

15 August 2017

Barbara A Haber

16

1 reference

15 August 2017

PEDS-C Clinical Research Network

17

1 reference

15 August 2017

language of work or name

English

0 references

publication date

1 March 2013

1 reference

Journal of Pediatric Gastroenterology and Nutrition

15 August 2017

1 reference

15 August 2017

56

1 reference

15 August 2017

3

1 reference

15 August 2017

304-310

1 reference

Autoimmune markers in diabetes

15 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3583208

The combination of ribavirin and peginterferon is superior to peginterferon and placebo for children and adolescents with chronic hepatitis C.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3583208

High sustained virologic response rates in children with chronic hepatitis C receiving peginterferon alfa-2b plus ribavirin

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3583208

Evolution and predictive factors of thyroid disorder due to interferon alpha in the treatment of hepatitis C.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3583208

Efficacy and safety of peginterferon-alpha2b and ribavirin combination therapy in children with chronic hepatitis C infection

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3583208

Design of the PEDS-C trial: pegylated interferon +/- ribavirin for children with chronic hepatitis C viral infection

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3583208

Evaluation of F-actin ELISA for the diagnosis of autoimmune hepatitis.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3583208

Late onset autoimmune thrombocytopenia associated with pegylated interferon-alpha-2b plus ribavirin treatment for chronic hepatitis C.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3583208

Recombinant alfa-interferon plus ribavirin therapy in children and adolescents with chronic hepatitis C.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3583208

Islet cell and thyroid antibody prevalence in patients with hepatitis C virus infection: effect of treatment with interferon

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3583208

Extrahepatic manifestations associated with hepatitis C virus infection. A prospective multicenter study of 321 patients. The GERMIVIC. Groupe d'Etude et de Recherche en Medecine Interne et Maladies Infectieuses sur le Virus de l'Hepatite C.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3583208

Autoantibody prevalence in children with liver disease due to chronic hepatitis C virus (HCV) infection

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3583208

Serum autoantibodies in chronic hepatitis C: comparison with autoimmune hepatitis and impact on the disease profile

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3583208

High prevalence of serological markers of autoimmunity in patients with chronic hepatitis C.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3583208

Peginterferon alfa-2b plus ribavirin treatment in children and adolescents with chronic hepatitis C.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3583208

Thyroid abnormalities in chronic viral hepatitis and their relationship to interferon alfa therapy

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3583208

Non-organ specific autoantibodies in children with chronic hepatitis C.

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3583208

Thyroid dysfunction in patients with chronic hepatitis C: virus- or therapy-related?

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3583208

Severe autoimmune hemolytic anemia complicated with liver decompensation and invasive aspergillosis in a patient with chronic hepatitis C during treatment with peg-interferon-a and ribavirin

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3583208

Interferon-induced thyroid dysfunction in chronic hepatitis C.

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3583208

High incidence of type 1 diabetes mellitus during or shortly after treatment with pegylated interferon alpha for chronic hepatitis C virus infection.

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3583208

Hepatitis C virus infection associated with liver-kidney microsomal antibody type 1 (LKM1) autoantibodies in children.

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3583208

Stability of autoantibodies and their relation to genetic and metabolic markers of Type I diabetes in initially unaffected schoolchildren.

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3583208

A comparison of the prevalence of autoantibodies in individuals with chronic hepatitis C and those with autoimmune hepatitis: the role of interferon in the development of autoimmune diseases

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3583208

Interferon Alpha Treatment and Endocrine Disease

20 September 2018

1 reference

12 December 2020

Silent celiac disease in chronic hepatitis C: impact of interferon treatment on the disease onset and clinical outcome

1 reference

12 December 2020

Efficacy and safety of interferon alfa therapy in chronic hepatitis C with autoantibodies to liver-kidney microsomes

1 reference

12 December 2020

Interferon-alpha therapy may induce insulin autoantibody development in patients with chronic viral hepatitis

1 reference

12 December 2020

Thyroid dysfunction in antiviral therapy of chronic hepatitis C

1 reference

12 December 2020

10.1097/MPG.0B013E3182774CAE

Identifiers

DOI

1 reference

15 August 2017

1 reference

15 August 2017

1 reference